Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study

NCT01498055 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2012-03-22

No results posted yet for this study

Summary

To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung cancer.

Conditions

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Principal Investigators

  • Xiangdong Zhou · Southwest Hospital Third Military University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498055 on ClinicalTrials.gov